目的:评价吡美莫司在特应性皮炎维持治疗中的作用。方法:74例AD病变缓解的患者随机接受1%吡美莫司乳膏或润肤剂4周的治疗。在研究结束时测量所有随机患者的湿疹面积和严重程度指数,评估复发率。结果:在研究结束时,复发患者吡美莫司乳膏治疗组中占24.3% (9/37),而在润肤剂组中占62.2% (23/37),差异有统计学意义。两组间均无不良反应发生。结论:局部外用吡美莫司能够抑制皮肤炎症浸润复发,可有效维持AD缓解,安全性较好。Objective: To evaluate the efficacy of pimecrolimus in maintenance therapy for atopic dermatitis. Method: 74 patients with relieved AD were randomly treated with 1% pimecrolimus cream or moisturizer for 4 weeks. Measure the eczema area and severity index of all randomized patients at the end of the study to evaluate the recurrence rate. Result: At the end of the study, 24.3% (9/37) of recurrent patients were treated with pimecrolimus cream, while 62.2% (23/37) were treated with moisturizer, with a statistically significant difference. No adverse reactions occurred between the two groups. Conclusion: Topical application of pimecrolimus can inhibit the infiltration and recurrence of skin inflammation, effectively maintain AD remission, and have fewer adverse reactions.
目的:探讨分析吡美莫司乳膏与火把花根片联合308准分子激光治疗白癜风的临床效果。方法:选择我院收治的白癜风患者80例,随机分为观察组和对照组,每组40例,对照组采用火把花根片联合308准分子激光治疗,观察组在与对照组相同治疗的基础上联合吡美莫司乳膏治疗。结果:观察组治疗总有效率90.00%,显著优于对照组72.50%,差异有统计学意义(P 0.05)。结论:吡美莫司乳膏与火把花根片联合308准分子激光治疗白癜风,疗效显著,不良反应少。 Objective: This study aimed to observe the clinical efficacy of 308 nm excimer laser combined with tacrolimus and colquhounia root tablet in the treatment of vitiligo. Method: 80 patients with vitiligo were randomly divided into an observation group and a control group, with 40 cases in each group. The control group was treated with colquhounia root tablet combined with 308 excimer laser, while the observation group was treated with Pimecrolimus cream in addition to the same treatment as the control group. Result: The total effective rate of the observation group was 90.00%, significantly higher than the control group’s 72.50%, and the difference was statistically significant (P 0.05). Conclusion: The combination of pimecrolimus cream and colquhounia root tablet with 308 excimer laser treatment for vitiligo improves efficacy and has fewer adverse reactions.
